ProCE Banner Activity

How I Use Venetoclax/Rituximab in Relapsed/Refractory CLL

Clinical Thought
How will the treatment landscape for CLL change with the recent approval of venetoclax/rituximab in R/R disease regardless of del(17p) status? Here’s my take.

Released: July 24, 2018

Expiration: July 23, 2019

No longer available for credit.

Share

Faculty

Danielle M. Brander

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Acerta Pharma AstraZeneca Group

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Danielle M. Brander, MD, has disclosed that she has received consulting fees from Genentech, Novartis, Pharmacyclics, and Teva and fees for non-CME services from AbbVie and TG Therapeutics.